To evaluate the anticoagulation effect of low molecular heparin and sulfonda heparan sodium after intertrochanteric fracture with thromboelastography

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040576

Enrollment

Unknown

Registered

2020-12-03

Start date

2020-12-31

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intertrochanteric fracture of femur

Interventions

A:Combined with thromboelastic diagram

B:Low molecular weight heparin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Unilateral operation for intertrochanteric fracture; 2) Aged 18 to 80 years; 3) Male or female; 4) The patient agrees to participate in the trial and signs the informed consent.

Exclusion criteria

Exclusion criteria: Congenital clotting dysfunction, liver dysfunction, renal insufficiency (creatinine clearance rate < 30 mL/min), acute cardio-cerebrovascular disease, hyperspleenism, tumor, previous history of thromboembolism, preoperative anticoagulant, antiplatelet therapy, preoperative thromboelastin examination abnormal, blood vessel color doppler ultrasonography indicating deep venous thrombosis

Design outcomes

Primary

Measure	Time frame
Thromboelastic diagram parameters;	—

Contacts

Public ContactGouYongSheng

Chengdu Shuangliu District First People's Hospital

15002828117@qq.com+86 15002828117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026